Skip to main content
padlock icon - secure page this page is secure

Mycophenolate mofetil substitution for cyclosporine‐dependent myasthenia gravis and nephrotoxicity

Buy Article:

$52.00 + tax (Refund Policy)

Severe autoimmune myasthenia gravis is difficult to manage and may require immunosuppression with cyclosporine. However, cyclosporine dependency is associated with the risk of nephrotoxicity. Mycophenolate mofetil is a non‐nephrotoxic alternative which should be considered to rescue cyclosporine‐dependent, severe myasthenia gravis sufferers with renal impairment from progression to end‐stage renal failure. However, the evidence is limited and studies have not assessed the outcome of a direct substitution in these cyclosporine‐dependent patients. We study three such patients who successfully converted to mycophenolate mofetil, and briefly examine the evidence behind this option. We believe that total cyclosporine withdrawal is feasible, but strongly recommend overlapping mycophenolate mofetil treatment with cyclosporine.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: cyclosporine; myasthenia gravis; mycophenolate mofetil; nephrotoxicity

Document Type: Research Article

Affiliations: Neurology, Austin Health, Melbourne, Victoria, Australia

Publication date: January 1, 2007

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more